Repatha (evolocumab)

pCPA File Number: 22524
Negotiation Status:
Concluded with an LOI
Indication(s):
Primary hyperlipidemia and mixed dyslipidemia
Sponsor/Manufacturer:
Amgen Canada Inc.
CDA-AMC Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded: